Evidence map›Paper›PMID 28823723›Full record

ArticleSchizophrenia research2018

Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation.

Susan Whitfield-Gabrieli, Adina S Fischer, Angela M Henricks, Jibran Y Khokhar, Robert M Roth, Mary F Brunette, Alan I Green

Abstract read
In one paragraph

Article in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Cannabis and Tobacco Co-Use Predicts Psychosis in Clinical High Risk Cohorts.medRxiv : the preprint server for health sciences · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Altered amygdala-cortical connectivity in individuals with Cannabis use disorder.Journal of psychopharmacology (Oxford, England) · 2021
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Susan Whitfield-GabrieliDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.
Adina S FischerDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Angela M HenricksDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Jibran Y KhokharDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Robert M RothDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Mary F BrunetteDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Alan I GreenDepartment of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, NH, USA; Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA; Dartmouth Clinical and Translational Science Institute, Dartmouth College, Hanover, NH, USA. Electronic address: Alan.I.Green@dartmouth.edu.

Funding

Training in the Science of Co-Occurring DisordersT32DA037202 · NIDA · DARTMOUTH COLLEGE · PI Lisa A. Marsch · 2014 to 2026
$4.7M
Cannabis and Schizophrenia: Self-Medication and Agonist Treatment?R01DA026799 · NIDA · DARTMOUTH COLLEGE · PI GREEN, ALAN I · 2009 to 2010
$1.1M
NIDA NIH HHS R01 DA026799NIDA NIH HHS T32 DA037202
6 · The paper itself

Abstract

Nearly half of patients with schizophrenia (SCZ) have co-occurring cannabis use disorder (CUD), which has been associated with decreased treatment efficacy, increased risk of psychotic relapse, and poor global functioning. While reports on the effects of cannabis on cognitive performance in patients with SCZ have been mixed, study of brain networks related to executive function may clarify the relationship between cannabis use and cognition in these dual-diagnosis patients. In the present pilot study, patients with SCZ and CUD (n=12) and healthy controls (n=12) completed two functional magnetic resonance imaging (fMRI) resting scans. Prior to the second scan, patients smoked a 3.6% tetrahydrocannabinol (THC) cannabis cigarette or ingested a 15mg delta-9-tetrahydrocannabinol (THC) pill. We used resting-state functional connectivity to examine the default mode network (DMN) during both scans, as connectivity/activity within this network is negatively correlated with connectivity of the network involved in executive control and shows reduced activity during task performance in normal individuals. At baseline, relative to controls, patients exhibited DMN hyperconnectivity that correlated with positive symptom severity, and reduced anticorrelation between the DMN and the executive control network (ECN). Cannabinoid administration reduced DMN hyperconnectivity and increased DMN-ECN anticorrelation. Moreover, the magnitude of anticorrelation in the controls, and in the patients after cannabinoid administration, positively correlated with WM performance. The finding that DMN brain connectivity is plastic may have implications for future pharmacotherapeutic development, as treatment efficacy could be assessed through the ability of therapies to normalize underlying circuit-level dysfunction.

Indexed as

AdultBrainBrain MappingComorbidityDronabinolFemaleHumansMagnetic Resonance ImagingMaleMarijuana AbuseMemory, Short-TermNeural PathwaysPilot ProjectsPsychotropic DrugsRestSchizophreniaDronabinolPsychotropic DrugsCannabis use disorderDefault mode networkfMRIResting state functional connectivitySchizophrenia

Identifiers

PMID28823723
PMCPMC6886576

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.